FibroGen (NASDAQ: FGEN) announced that Nephrology Dialysis Transplantation has published encouraging Phase 2a safety and efficacy data for roxadustat, an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments

FibroGen (FGEN) Tops Q2 EPS by 10cAugust 13, 2015 4:47 PM Nephrology Dialysis Transplantation Reports Phase 2 Data of Investigational Orally Active HIF-PHI Roxadustat (FG-4592) Shows Improved Hemoglobin Levels in Non-Dialysis CKD Subjects With AnemiaAugust 12, 2015 6:18 PM Nephrology Dialysis Transplantation Reports Phase 2 Data of Investigational Orally Active HIF-PHI Roxadustat (FG-4592) Shows Improved Hemoglobin Levels in Non-Dialysis CKD Subjects With AnemiaAugust 12, 2015 6:18 PM Form 8-K FIBROGEN INC For: Aug 06August 12, 2015 5:18 PM